Amneal Pharmaceuticals
S&P 600
$17.01
+0.83%
Delayed · cached 15 min
Fair value analysis
AMRX
Amneal Pharmaceuticals
$17.01
Close used for this calculation
$9.24Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
42/100
Quality radar
Consensus fair value
$9.24
Above FV▼ -45.7% against the close used
Model range $4.40 – $15.45
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$4.40Fair value$9.24Bull$15.45
FairClose
52-week traded range
52W low $9.6052W high $19.10
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Amneal Pharmaceuticals closed at $17.01, 84.1% above the consensus fair value of $9.24 drawn from 6 valuation models.
Financial DNA score 42/100 — Average. P/E of 77.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$15.45
-9.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
P/E Fair Value
$4.40
-74.1%
EPS × 20x (sector P/E)
EPS=0.22, Sector P/E=20x
Peter Lynch (PEG)
$6.60
-61.2%
EPS × Growth% (PEG = 1 is fair)
EPS=0.22, g=30%
EV/EBITDA
$6.79
-60.1%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=451.4M
Reverse DCF
$17.01
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 25.5% | Historical: -40%
Margin of Safety
$7.44
-56.2%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=9.93, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.